American biotech firm Halozyme Therapeutics (Nasdaq: HALO) has released positive news from a much-anticipated Phase II trial of the company’s lead investigational compound.
PEGPH20, an anticancer agent, is designed to make existing treatments more effective by breaking down potential barriers to the tumor.
Shares in the company jumped more than 20% to $13 before markets opened. Strong investor interest continues to support higher than average volumes of trading in the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze